EADV 2022 update on biologics and JAK-inhibitors for the treatment of atopic dermatitis  

In line with an increased knowledge of the pathophysiological factors in atopic dermatitis, this year’s EADV 2022 presents real-world data for the Janus kinase inhibitor baricitinib and an update on the biologic drug dupilumab for moderate-to-severe AD.